N/A
Completed N=294,878
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
Source: ClinicalTrials.gov NCT04746989 ↗Enrolled (actual)
294,878
Serious AEs
—
Results posted
Feb 2026
Primary outcomePrimary: Time to Dementia Onset — 14.44; 18.23; 22.07; 19.40 Incidence rate per 1000 person year
Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Dementia Onset |
14.44; 18.23; 22.07; 19.40; 15.87; 17.54 | — |
Eligibility Criteria
Please see https://docs.google.com/spreadsheets/d/1N3IVoirGdWS7OiKiOWWgPHhgsSxX7SWDIhpeeZ-Ft7c/edit?usp=sharing or Appendix A for full code and algorithm definitions.
Medicare timeframe: 2007 to 2017 (end of data availability).
Inclusion Criteria
- 1. No prior use of urate-lowering agents, including probenecid and allopurinol anytime prior to cohort entry date
- 2. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date
Exclusion Criteria
- 1. Prior history of dementia measured anytime prior to cohort entry date
- 2. No prior history of gout recorded in the 365 days prior to cohort entry date
- 3. Prior history of nursing home admission in the 365 days prior to the cohort entry date
Data sourced from ClinicalTrials.gov (NCT04746989). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.